Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 196

Similar articles for PubMed (Select 19936252)

1.

Lrp4, a novel receptor for Dickkopf 1 and sclerostin, is expressed by osteoblasts and regulates bone growth and turnover in vivo.

Choi HY, Dieckmann M, Herz J, Niemeier A.

PLoS One. 2009 Nov 20;4(11):e7930. doi: 10.1371/journal.pone.0007930.

2.

Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity.

Ellies DL, Viviano B, McCarthy J, Rey JP, Itasaki N, Saunders S, Krumlauf R.

J Bone Miner Res. 2006 Nov;21(11):1738-49.

PMID:
17002572
3.

Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling.

Li X, Zhang Y, Kang H, Liu W, Liu P, Zhang J, Harris SE, Wu D.

J Biol Chem. 2005 May 20;280(20):19883-7. Epub 2005 Mar 18.

4.

Disruption of Lrp4 function by genetic deletion or pharmacological blockade increases bone mass and serum sclerostin levels.

Chang MK, Kramer I, Huber T, Kinzel B, Guth-Gundel S, Leupin O, Kneissel M.

Proc Natl Acad Sci U S A. 2014 Dec 2;111(48):E5187-95. doi: 10.1073/pnas.1413828111. Epub 2014 Nov 17.

5.

The binding between sclerostin and LRP5 is altered by DKK1 and by high-bone mass LRP5 mutations.

Balemans W, Piters E, Cleiren E, Ai M, Van Wesenbeeck L, Warman ML, Van Hul W.

Calcif Tissue Int. 2008 Jun;82(6):445-53. doi: 10.1007/s00223-008-9130-9.

PMID:
18521528
6.

Analysis of association of LRP5, LRP6, SOST, DKK1, and CTNNB1 genes with bone mineral density in a Slovenian population.

Mencej-Bedrac S, Prezelj J, Kocjan T, Komadina R, Marc J.

Calcif Tissue Int. 2009 Dec;85(6):501-6. doi: 10.1007/s00223-009-9306-y. Epub 2009 Nov 7.

PMID:
19898734
7.

Mesd is a universal inhibitor of Wnt coreceptors LRP5 and LRP6 and blocks Wnt/beta-catenin signaling in cancer cells.

Lu W, Liu CC, Thottassery JV, Bu G, Li Y.

Biochemistry. 2010 Jun 8;49(22):4635-43. doi: 10.1021/bi1001486.

8.

Bone overgrowth-associated mutations in the LRP4 gene impair sclerostin facilitator function.

Leupin O, Piters E, Halleux C, Hu S, Kramer I, Morvan F, Bouwmeester T, Schirle M, Bueno-Lozano M, Fuentes FJ, Itin PH, Boudin E, de Freitas F, Jennes K, Brannetti B, Charara N, Ebersbach H, Geisse S, Lu CX, Bauer A, Van Hul W, Kneissel M.

J Biol Chem. 2011 Jun 3;286(22):19489-500. doi: 10.1074/jbc.M110.190330. Epub 2011 Apr 6.

9.

LRP4 association to bone properties and fracture and interaction with genes in the Wnt- and BMP signaling pathways.

Kumar J, Swanberg M, McGuigan F, Callreus M, Gerdhem P, Akesson K.

Bone. 2011 Sep;49(3):343-8. doi: 10.1016/j.bone.2011.05.018. Epub 2011 May 27.

PMID:
21645651
10.

Wnt inhibitors Dkk1 and Sost are downstream targets of BMP signaling through the type IA receptor (BMPRIA) in osteoblasts.

Kamiya N, Kobayashi T, Mochida Y, Yu PB, Yamauchi M, Kronenberg HM, Mishina Y.

J Bone Miner Res. 2010 Feb;25(2):200-10. doi: 10.1359/jbmr.090806.

11.

Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma.

Qiang YW, Barlogie B, Rudikoff S, Shaughnessy JD Jr.

Bone. 2008 Apr;42(4):669-80. doi: 10.1016/j.bone.2007.12.006. Epub 2007 Dec 27.

PMID:
18294945
12.

Modulation of sclerostin expression by mechanical loading and bone morphogenetic proteins in osteogenic cells.

Papanicolaou SE, Phipps RJ, Fyhrie DP, Genetos DC.

Biorheology. 2009;46(5):389-99. doi: 10.3233/BIR-2009-0550.

PMID:
19940355
13.

SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor.

Semënov M, Tamai K, He X.

J Biol Chem. 2005 Jul 22;280(29):26770-5. Epub 2005 May 20.

14.

Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia.

Li J, Sarosi I, Cattley RC, Pretorius J, Asuncion F, Grisanti M, Morony S, Adamu S, Geng Z, Qiu W, Kostenuik P, Lacey DL, Simonet WS, Bolon B, Qian X, Shalhoub V, Ominsky MS, Zhu Ke H, Li X, Richards WG.

Bone. 2006 Oct;39(4):754-66. Epub 2006 May 26.

PMID:
16730481
15.

Anti-Sclerostin antibody inhibits internalization of Sclerostin and Sclerostin-mediated antagonism of Wnt/LRP6 signaling.

van Dinther M, Zhang J, Weidauer SE, Boschert V, Muth EM, Knappik A, de Gorter DJ, van Kasteren PB, Frisch C, Mueller TD, ten Dijke P.

PLoS One. 2013 Apr 29;8(4):e62295. doi: 10.1371/journal.pone.0062295. Print 2013.

16.

Lrp5 and Lrp6 exert overlapping functions in osteoblasts during postnatal bone acquisition.

Riddle RC, Diegel CR, Leslie JM, Van Koevering KK, Faugere MC, Clemens TL, Williams BO.

PLoS One. 2013 May 10;8(5):e63323. doi: 10.1371/journal.pone.0063323. Print 2013.

17.

Where Wnts went: the exploding field of Lrp5 and Lrp6 signaling in bone.

Williams BO, Insogna KL.

J Bone Miner Res. 2009 Feb;24(2):171-8. doi: 10.1359/jbmr.081235. Review.

18.

Sclerostin regulates release of bone mineral by osteocytes by induction of carbonic anhydrase 2.

Kogawa M, Wijenayaka AR, Ormsby RT, Thomas GP, Anderson PH, Bonewald LF, Findlay DM, Atkins GJ.

J Bone Miner Res. 2013 Dec;28(12):2436-48. doi: 10.1002/jbmr.2003.

PMID:
23737439
19.

Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass.

Morvan F, Boulukos K, Clément-Lacroix P, Roman Roman S, Suc-Royer I, Vayssière B, Ammann P, Martin P, Pinho S, Pognonec P, Mollat P, Niehrs C, Baron R, Rawadi G.

J Bone Miner Res. 2006 Jun;21(6):934-45.

PMID:
16753024
20.

Sclerostin inhibition reverses skeletal fragility in an Lrp5-deficient mouse model of OPPG syndrome.

Kedlaya R, Veera S, Horan DJ, Moss RE, Ayturk UM, Jacobsen CM, Bowen ME, Paszty C, Warman ML, Robling AG.

Sci Transl Med. 2013 Nov 13;5(211):211ra158. doi: 10.1126/scitranslmed.3006627.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk